Antitumor effect of GnRH agonist in epithelial ovarian cancer

Gynecologic Oncology

Volumn 74, Issue 2, 1999, Pages 170-180

  Kim, Jae Hoon ^a   Park, Dong Choon ^a   Kim, Jin Woo ^b   Choi, Yang Kyu ^c   Lew, Young Ok ^a   Kim, Dae Hoon ^a   Jung, Jae Keun ^d   Lim, Young Ae ^e   Namkoong, Sung Eun ^b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Korea Institute of Science and Technology   (South Korea)

^d The Catholic University of Korea   (South Korea)

^e Ajou University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; GONADORELIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CONTROLLED STUDY; CYTOSTASIS; FEMALE; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; TUMOR GROWTH;

EID: 0344172789     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1999.5413     Document Type: Article

References (51)

1. Korean Association of Obstetricians and Gynecologists, Gynecologic Cancer Registry Program in Korean Women, 1994
2. Christian MC, Trimble EL: Salvage chemotherapy for epithelial ovarian carcinoma. Gynecol Oncol 55:S143-150, 1994
3. Imai A, Ohno T, Iida K, Fuseya T, Furui T, Tamaya T: Gonadotropin-releasing hormone receptor in gynecologic tumors, frequent expression in adenocarcinoma histologic types. Cancer 74(9):2555-2561, 1994
4. Kaiser UB, Conn PM, Chin WW: Studies of gonadotropin-releasing hormone (GnRH) action using GnRH receptor expressing pituitary cell lines. Endocr Rev 18(1):46-70, 1997
5. Chatzaki E, Bax CM, Eidne KA, Anderson L, Grudzinskas JG, Gallagher CJ: The expression of gonadotropin-releasing hormones and its receptor in endometrial cancer, and its relevance as an autocrine growth factor. Cancer Res 56:2059-2065, 1996
6. Marini L, Iacopino F, Schinzari G, Robustelli Della Cuna FS, Mantovani G, Sica G: Direct antiproliferative effect of triptorelin on human breast cancer cells. Anticancer Res 14:1881-1885, 1994
7. Kullander S, Rausing A, Trope C: Human ovarian tumors heterotransplanted to nude mice. Acta Obstet Gynecol Scand 57(2): 149-159, 1978
8. Peterson CM, Jolles CJ, Carrell DT, Straight RC, Jones KP, Poulson AM, Hatasaka HH: GnRH agonist therapy in human ovarian epithelial carcinoma (OVCAR-3) heterotransplanted in the nude mouse is characterized by latency and transience. Gynecol Oncol 52(1):26-30, 1994
9. Yano T, Pinski J, Halmons G, Szepeshazi K, Groot K, Schally AV: Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75. Proc Natl Acad Sci USA 91(5):7090-7094, 1994
10. Yano T, Pinski J, Radulovic S, Schally AV: Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 91(5):1701-1705, 1994
11. Manetta A, Liao S, Gamboa-Vujicic G, Leong L, Pardes P, Asch B, Emma D, Schally A: Inhibition of growth of human ovarian cancer in nude mice by luteinizing hormone-releasing hormone antagonist cetrorelix (SB-75). Fertil Steril 63(2):282-287, 1995
12. Vincze B, Palyi I, Gaal D, Pato J, Mora M, Mezo I, Teplan I, Seprodi J: In vivo studies of the new gonadotropin-releasing hormone antagonist-copolymer conjugates having antitumor activity. Cancer Detect Prev 20(2):153-159, 1996
13. Emons G, Ortmann O, Teichert HM, Fassl H, Lohrs U, Kullander S, Kauppila A, Ayalon D, Schally A, Oberheuser F: Luteinizing hormone releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group Cancer 78(7):1452-1460, 1996
14. Falkson CI, Falkson HC, Falkson G: Cisplatin versus cisplatin plus D-TRP-6-LHRH in the treatment of ovarian cancer: A pilot trial to investigate the effect of the addition of a GnRH analogue to cisplatin. Oncology 53(4):313-317, 1996
15. van-der Vange N, Greggi S, Burger CW, Kenemans P, Vermorken JB: Experience with hormonal therapy in advanced epithelial ovarian cancer. Acta Oncol 34(6):813-820, 1995
16. Sharma HW, Sokoloski JA, Perez JR, Maltese JY, Sartorelli AC, Stein CA, Nicholas G, Khaled Z, Telang NT, Narayanan R: Differentiation of immortal cells inhibits telomerase activity. Proc Natl Acad Sci USA 92(26):12343-12346, 1995
17. Albanell J, Han W, Mellado B, Gunawardane R, Scher HI, Dmitrovsky E, Moore MA: Telomerase activity is repressed during differentiation of maturation-sensitive but not resistant human tumor cell lines. Cancer Res 56(7):1503-1508, 1996
18. Avilion AA, Piatyszek MA, Gupta J, Shay JW, Bacchetti S, Greider CW: Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues. Cancer Res 56(3):645-650, 1996
19. Choi YK, Choi JY, Kown EH, Kim YJ, Lee CH, Jeong KS, Hyun BH: Evaluation of nonleaky C.B-17 SCID mice by ELISA. Korean J Lab Anti Sci 12:9-13, 1996
20. Carmichael J, Degraff WG, Gazdar AF, Minna JD, Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of chemosensitivity testing. Cancer Res 47(4):936-942, 1987
21. Choi YK, Choi JY, Hyun BH, Kim YJ, Lee CH, Yoon WK, Jeong KS, Kim DY: Antitumor effect of methotrexate in SCID mice with human leukemia CCRF-CEM cell line. Korean Cancer Assoc 29:19-28, 1997
22. Beavis AJ, Pennline KJ: Allo-7: A new fluorescent tandem dye for use in flow cytometry. Cytometry 24(4):390-395, 1996
23. Bonfoco E, Krainc D, Ankarcrona M, Nicotera P, Lipton SA: Apoptosis and necrosis: Two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. Proc Natl Acad Sci USA 92(16):7162-7166, 1995
24. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015, 1994
25. Snedecor GW, Cochran WG: Statistics Methods, 2nd ed. Iowa State Univ. Press, Ames, Iowa, 1980
26. Miller RG Jr: Survival Analysis. Wiley, New York, 1981
27. Desombre ER, Holt JA, Herbst AL: Steroid receptors in breast, uterine and ovarian malignancy, in: Gold JJ, Josinovich JB (Eds.): Gynecologic Endocrinology. Plenum, New York, 1987, pp. 511-528
28. Rao BR, Slotman BJ: Endocrine factors in common epithelial ovarian cancer. Endocr Rev 12(1):14-26, 1991
29. Stadel BV: The etiology and prevention of ovarian cancer. Am J Obstet Gynecol 123:772-774, 1975
30. Cramer DW, Welch WR: Determinants of ovarian cancer risk II. Inferences regarding pathogenesis. J Natl Cancer Inst 71:717-721, 1983
31. Schlesselman JJ: Cancer of the breast and reproductive tract in relation to use of oral contraceptives. Contraception 40(1):1-38, 1989
32. Simon WE, Albrecht M, Haensel M, Dietel M, Hoelzel F: Cell lines derived from human ovarian carcinomas: Growth stimulation by gonadotropic and steroid hormones. J Natl Cancer Inst 70:839-845, 1983
33. Ohtani K: Effects of gonadotropin on the growth of malignant ovarian neoplasms assessed by subdural capsule assay. Nippon Sanka Fujinka Gakki Zasshi 42:579-585, 1990
34. Mortel R, Satyaswaroop PG, Schally AV, Hamilton T, Ozols R: Inhibitory effect of GnRH superagonist on the growth of human ovarian carcinoma NIH: OVCAR 3 in the nude mouse. Gynecol Oncol 23:254-255, 1986
35. Kullander S, Rausing A, Schally AV: LHRH agonist treatment in ovarian cancer, in klijn (Ed): Hormonal Manipulation of Cancer: Peptides, Growth Factors and New (Anti) Steroidal Agents. Raven Press, New York, 1987, pp. 353-356
36. Emons G, Schally AV: The use of lutenizing hormone releasing hormone agonists (antagonists) in gynecological cancers. Hum Reprod 9(7):1364-1379, 1994
37. Ron IG, Wigler N, Merimsky O, Inbar MJ, Chaitchik S: A phase II trial of D-TRP-6-LHRH (Decapeptyl) in pretreated patients with advanced epithelial ovarian cancer. Cancer Invest 13(3):272-275, 1995
38. Thompson MA, Adelson MD, Kaufman LM: Lupron retards proliferation of ovarian epithelial tumor cells cultured in serum-free medium. J Clin Endocrinol Metab 72:1036-1041, 1991
39. Shibata S, Sato H, Ota H, Karube A, Takahashi O, Tanaka T: Involvement of annexin V in antiproliferative effects of gonadotropin-releasing hormone agonist on human endometrial cancer cell line. Gynecol Oncol (2)66:217-221, 1997
40. Ho MN, Delgado CH, Owens GA, Steller MA: Insulin-like growth factor-II participates in the biphasic effect of a gonadotropin-releasing hormone agonist on ovarian cancer cell growth. Fertil Steril 67(5):870-876, 1997
41. Ohno T, Imai A, Furui T, Takahashi K, Tamaya T: Presence of gonadotropin-releasing hormone and its messenger ribonucleic acid in human ovarian epithelial carcinoma. Am J Obstet Gynecol 169:605-610, 1993
42. Emons G, Ortman O, Pahwa GS, Oberheuser F, Schultz KD: Intracellular actions of gonadotropic and peptide hormones and the therapeutic value of GnRH-agonists in ovarian cancer. Acta Obstet Gynecol Scan Suppl 155: 31-38, 1992
43. Ackerman RC, Johson GA, Van Kirk EA, Asirvatham AL, Murdoch WJ: Induction of apoptotic or lytic death in ovarian adenocarcinoma cell line by antibodies generated against a synthetic N-terminal extracellular domain gonadotropin-releasing hormone receptor peptide. Cancer Lett 81: 177-184, 1994
44. Emons G, Ortmannm O, Becker M, Irmer G, Springer B, Laun R, Hoelzel F, Schulz KD, Schally AV: High affinity binding and direct antiproliferative effects of LH-RH analogues in ovarian cancer cell lines. Cancer Res 54:5439-5446, 1993
45. Alaoui SE, Lawry J, Griffin M: The cell cycle and induction of apoptosis in a hamster fibrosarcoma cell line treated with anti-cancer drugs: Its importance to solid tumor chemotherapy. J Neurooncol 31:195-207, 1997
46. Bergers E, Mntironi R, van Diest PJ, Prete E, Baak JPA, Fiac(Hon) F: Interlaboratory reproducibility of semiautomated cell cycle analysis of flow cytometric DNA-histograms obtained from fresh material of 1,295 breast cancer cases. Hum Pathol 27(6):553-560, 1995
47. Gibb RK, Taylor DD, Wan T, Oconnor DM, Doering DL, Gercel-Taylor C: Apoptosis as a measure of chemosensitivity to cisplatin and taxol therapy in ovarian cancer cell lines. Gynecol Oncol 65(1):13-22, 1997
48. Buchkovich KJ, Greider, CW: Telomerase regulation during entry into the cell cycle in normal human T cells. Mol Biol Cell 7:1443-1454, 1996
49. Zhu X, Kumar R, Mandal M, Sharma N, Scharma HW, Dhingra U, Sokoloski JA, Hsiao R, Narayanan R: Cell cycle-dependent modulation of telomerase activity in tumor cells. Proc Natl Acad Sci USA 93:6091-6095, 1996
50. Sokoloski JA, Blair OC, Carbone R, Sartorelli AC: Induction of the differentiation of synchronized HL-60 leukemia cells by tiazofurin. Exp Cell Res 182:234-241, 1989
51. Ozols RF, Rubin SC, Dembo AJ, Robboy S: Epithelial ovarian cancer, in Hoskins WJ, Perez SA, Young RC (Eds.): Principles and Practice of Gynecologic Oncology. Philadelphia, Lippincott 1992, 731-781